Biomarkers in the Management of Heart Failure

Overview

Journal Curr Treat Options Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2010 Nov 11

PMID 21063930

Citations 6

Authors

Han-Na Kim

James L Januzzi Jr

Affiliations

Soon will be listed here.

Abstract

Biomarkers, especially natriuretic peptides such as B-type natriuretic peptide (BNP) and N-terminal-proBNP (NT-proBNP), are a valuable addition to standard clinical assessment in the diagnosis and prognosis of heart failure (HF). Furthermore, there is an increasing amount of evidence suggesting that natriuretic peptide-guided HF management may improve mortality, morbidity, and cost effectiveness. This work focuses on the use of BNP or NT-proBNP for the outpatient management of patients with chronic HF.

Citing Articles

Overactive Bladder is a Distress Symptom in Heart Failure.

Son Y, Kwon B Int Neurourol J. 2018; 22(2):77-82.

PMID: 29991228 PMC: 6059908. DOI: 10.5213/inj.1836120.060.

Redefining biomarkers in heart failure.

Correale M, Monaco I, Brunetti N, Di Biase M, Metra M, Nodari S Heart Fail Rev. 2018; 23(2):237-253.

PMID: 29511896 DOI: 10.1007/s10741-018-9683-2.

Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure.

Ahmad T, Fiuzat M, Neely B, Neely M, Pencina M, Kraus W JACC Heart Fail. 2014; 2(3):260-8.

PMID: 24952693 PMC: 4224312. DOI: 10.1016/j.jchf.2013.12.004.

Managing therapeutic competition in patients with heart failure, lower urinary tract symptoms and incontinence.

Tannenbaum C, Johnell K Drugs Aging. 2013; 31(2):93-101.

PMID: 24357134 PMC: 3907694. DOI: 10.1007/s40266-013-0145-1.

Relative Change in NT-proBNP Level: An Important Risk Predictor of Cardiovascular Congestion in Haemodialysis Patients.

Pastural-Thaunat M, Ecochard R, Boumendjel N, Abdullah E, Cardozo C, Lenz A Nephron Extra. 2013; 2(1):311-8.

PMID: 23341833 PMC: 3551398. DOI: 10.1159/000343897.

References

Bhardwaj A, Januzzi Jr J . ST2: a novel biomarker for heart failure. Expert Rev Mol Diagn. 2010; 10(4):459-64. DOI: 10.1586/erm.10.25. View

Schou M, Gustafsson F, Videbaek L, Markenvard J, Ulriksen H, Ryde H . Design and methodology of the NorthStar Study: NT-proBNP stratified follow-up in outpatient heart failure clinics -- a randomized Danish multicenter study. Am Heart J. 2008; 156(4):649-55. DOI: 10.1016/j.ahj.2008.06.007. View

Bhardwaj A, Rehman S, Mohammed A, Baggish A, Moore S, Januzzi Jr J . Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study. Am Heart J. 2010; 159(4):532-538.e1. DOI: 10.1016/j.ahj.2010.01.005. View

Van Kimmenade R, Januzzi Jr J, Bakker J, Houben A, Rennenberg R, Kroon A . Renal clearance of B-type natriuretic peptide and amino terminal pro-B-type natriuretic peptide a mechanistic study in hypertensive subjects. J Am Coll Cardiol. 2009; 53(10):884-90. DOI: 10.1016/j.jacc.2008.11.032. View

Braunwald E . Biomarkers in heart failure. N Engl J Med. 2008; 358(20):2148-59. DOI: 10.1056/NEJMra0800239. View

Wu A . Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results. Am Heart J. 2006; 152(5):828-34. DOI: 10.1016/j.ahj.2006.08.021. View

Ryder M, Murphy N, McCaffrey D, OLoughlin C, Ledwidge M, McDonald K . Outpatient intravenous diuretic therapy; potential for marked reduction in hospitalisations for acute decompensated heart failure. Eur J Heart Fail. 2008; 10(3):267-72. DOI: 10.1016/j.ejheart.2008.01.003. View

Cleland J, Coletta A, Clark A, Cullington D . Clinical trials update from the American College of Cardiology 2009: ADMIRE-HF, PRIMA, STICH, REVERSE, IRIS, partial ventricular support, FIX-HF-5, vagal stimulation, REVIVAL-3, pre-RELAX-AHF, ACTIVE-A, HF-ACTION, JUPITER, AURORA, and OMEGA. Eur J Heart Fail. 2009; 11(6):622-30. DOI: 10.1093/eurjhf/hfp071. View

Manginas A, Tsiavou A, Sfyrakis P, Giamouzis G, Tsourelis L, Leontiadis E . Increased number of circulating progenitor cells after implantation of ventricular assist devices. J Heart Lung Transplant. 2009; 28(7):710-7. DOI: 10.1016/j.healun.2009.04.006. View

10.

Latini R, Masson S, Anand I, Judd D, Maggioni A, Chiang Y . Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2002; 106(19):2454-8. DOI: 10.1161/01.cir.0000036747.68104.ac. View

11.

Felker G, Hasselblad V, Hernandez A, OConnor C . Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J. 2009; 158(3):422-30. DOI: 10.1016/j.ahj.2009.06.018. View

12.

Januzzi Jr J, Sakhuja R, ODonoghue M, Baggish A, Anwaruddin S, Chae C . Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med. 2006; 166(3):315-20. DOI: 10.1001/archinte.166.3.315. View

13.

Marcus L, Hart D, Packer M, Yushak M, Medina N, Danziger R . Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation. 1996; 94(12):3184-9. DOI: 10.1161/01.cir.94.12.3184. View

14.

Piao F, Park S, Han J, Cao C, Kim S, Kim S . Dendroaspis natriuretic peptide and its functions in pig ovarian granulosa cells. Regul Pept. 2004; 118(3):193-8. DOI: 10.1016/j.regpep.2003.12.011. View

15.

Araujo J, Azevedo A, Lourenco P, Rocha-Goncalves F, Ferreira A, Bettencourt P . Intraindividual variation of amino-terminal pro-B-type natriuretic peptide levels in patients with stable heart failure. Am J Cardiol. 2006; 98(9):1248-50. DOI: 10.1016/j.amjcard.2006.06.017. View

16.

Schou M, Gustafsson F, Nielsen P, Madsen L, Kjaer A, Hildebrandt P . Unexplained week-to-week variation in BNP and NT-proBNP is low in chronic heart failure patients during steady state. Eur J Heart Fail. 2006; 9(1):68-74. DOI: 10.1016/j.ejheart.2006.05.001. View

17.

Porapakkham P, Porapakkham P, Zimmet H, Billah B, Krum H . B-type natriuretic peptide-guided heart failure therapy: A meta-analysis. Arch Intern Med. 2010; 170(6):507-14. DOI: 10.1001/archinternmed.2010.35. View

18.

Cohn J, Tam S, Anand I, Taylor A, Sabolinski M, Worcel M . Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT. J Card Fail. 2007; 13(5):331-9. DOI: 10.1016/j.cardfail.2007.03.001. View

19.

Rubattu S, Sciarretta S, Morriello A, Calvieri C, Battistoni A, Volpe M . NPR-C: a component of the natriuretic peptide family with implications in human diseases. J Mol Med (Berl). 2010; 88(9):889-97. DOI: 10.1007/s00109-010-0641-2. View

20.

Menardi E, Vado A, Rossetti G, Racca E, Conte E, Deorsola A . Cardiac resynchronization therapy modifies the neurohormonal profile, hemodynamic and functional capacity in heart failure patients. Arch Med Res. 2008; 39(7):702-8. DOI: 10.1016/j.arcmed.2008.07.004. View